Subscribe to Biotech Blueprint HERE.While the U.S. gears up for Independence Day, biotech is having its own kind of fireworks. In This Week in Biotech #59, we look at Regeneron landing a major approval for its BCMAxCD3 bispecific; AbbVie making a bold play in in vivo CAR-T; and Argenx entering the macrocyclic peptide race with a $1.5B AI-driven deal. Meanwhile, RFK Jr. quietly reshapes the vaccine injury landscape, with possible implications for every major COVID vaccine maker.Also inside: — China’s first dual GLP-1/GCG agonist approval — Moderna’s latest win in seasonal flu — Key updates on ACA coverage, RSV policy, and Alzheimer’s trials
No persons identified in this episode.
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster